Officer Stock Vesting and Ownership Update

Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., reported the vesting of 39,900 performance stock units (PSUs) on May 21, 2026. These PSUs, granted on August 19, 2025, represent a contingent right to receive one share of common stock per unit upon achievement of performance goals, which were certified on the reporting date. The vesting is subject to Sullivan's continued service until August 19, 2028. Following this transaction, Sullivan holds 40,323 shares of common stock directly. The price per share for this transaction was $0.0, indicating the PSUs were awarded based on performance rather than a purchase.